Latest Biotech News

FDA Commissioner Marty Makary announced a pilot program that will pay quarterly bonuses to drug reviewers who complete reviews ahead of schedule, according to slides and a staff presentation...

Atrium Therapeutics launched with a $270 million financing to advance two RNA therapy candidates for rare inherited cardiac conditions, the company said. Atrium spun out of Avidity Biosciences...

The Phase 3 LITESPARK‑022 trial reported that combining belzutifan, a HIF‑2α inhibitor, with pembrolizumab significantly improved disease‑free survival in high‑risk clear‑cell renal cell carcinoma...

Novartis presented preliminary Phase 2 data evaluating Rhapsido, a drug recently approved for chronic spontaneous urticaria, in food allergy. The company reported that all three investigational...

Researchers discovered that unrelated bacteriophages disable the essential bacterial cell‑wall protein MurJ by locking it into a single conformation, halting peptidoglycan assembly and causing...

Researchers reported a platinum complex that is activated by X‑rays to enhance radiotherapy efficacy and amplify anti‑tumor immune responses in preclinical models. The compound operates via a...

Researchers unveiled a chemiluminescent microfluidic chip with dielectric wetting valves that non‑invasively measures embryo metabolites to predict implantation potential. The device integrates...

A newly reported wearable device combines ultrasound actuation with microneedle drug delivery to provide both immediate and sustained therapy for gouty arthritis. Published in npj Flexible...

Atrium Therapeutics launched with $270 million in initial financing to develop RNA therapies for rare inherited cardiac conditions. The company spun out from Avidity Biosciences after Avidity’s...

FDA Commissioner Marty Makary announced a pilot program to pay bonuses to drug reviewers who complete reviews ahead of schedule, with the first quarterly payments expected in August. The plan ties...

The phase 3 LITESPARK-022 trial reported that combining belzutifan, a HIF-2α inhibitor, with pembrolizumab significantly improved disease-free survival in high-risk clear cell renal cell carcinoma...

Novartis reported Phase 2 data indicating its recently approved hives drug, Rhapsido, produced higher response rates across three doses in a food allergy study. Company investigators presented...

Merck has filed to expand Welireg’s label to include two combination regimens in kidney cancer pairing the HIF-2α inhibitor with Keytruda and with Lenvima, despite not yet having overall survival...

Scientists discovered that diverse bacteriophages produce proteins that disable MurJ, an essential bacterial lipid II flippase, locking it in a single conformation and halting cell-wall synthesis....

Researchers reported a novel platinum complex that is activated by X‑rays to boost cancer radiotherapy efficacy through mechanisms distinct from conventional radiosensitizers. Preclinical work...

IRB Barcelona consolidated core facilities to unveil Spain’s first end-to-end spatial omics workflow, offering integrated sample processing, spatial transcriptomics, imaging, and data analysis...

New work highlights how foundation-style multimodal models are transforming spatial multi-omic studies by integrating histopathology images with molecular maps to reveal cellular phenotypes in...

Researchers developed chemiluminescent microfluidic chips with dielectric wetting valves that noninvasively analyze embryo metabolites to predict implantation potential during IVF. The device...

A phase 3 trial (LITESPARK‑022) reported that adding the HIF‑2α inhibitor belzutifan to pembrolizumab improved disease‑free survival in patients with clear‑cell renal cell carcinoma at high risk...

FDA Commissioner Marty Makary announced a pilot program to award bonus payments to drug reviewers who complete reviews ahead of schedule, marking an operational shift in how the agency...